Vlad Vitoc, MD, MBA
About Vlad Vitoc, MD, MBA
Vlad Vitoc, MD, MBA, is the Founder and CEO of MAIA Biotechnology, Inc. He has over two decades of experience in the pharmaceutical industry, holding various leadership roles in medical affairs, strategic analysis, and oncology across multiple companies.
Work at MAIA Biotechnology
Vlad Vitoc serves as the Founder and CEO of MAIA Biotechnology, Inc. since 2018. Under his leadership, the company focuses on innovative approaches in biotechnology, particularly in the oncology sector. His role involves strategic oversight and direction for the company's initiatives and projects, leveraging his extensive background in medical affairs and oncology.
Previous Experience in Oncology and Medical Affairs
Vlad Vitoc has held several significant positions in the field of oncology and medical affairs. He worked at Cephalon as Director of Oncology Strategic Analysis & Planning from 2006 to 2009 and later as Sr Director in the same department from 2009 to 2011. His experience also includes serving as VP of Medical Affairs at Puma Biotechnology, Inc. from 2015 to 2018, and as Executive Medical Director at Incyte from 2014 to 2015.
Educational Background
Vlad Vitoc obtained his Medical Doctor (MD) degree from the University of Medicine and Pharmacy 'Iuliu Hațieganu' in Cluj-Napoca, where he studied Internal Medicine from 1990 to 1996. He furthered his education by earning a Master of Business Administration (MBA) in Marketing and International Business from the University of South Carolina, completing his studies from 1998 to 2000.
Leadership and Strategic Skills
Vlad Vitoc possesses strong analytical and interpersonal skills, which facilitate pragmatic implementation across medical, commercial, and clinical development sectors. He has extensive experience in leading clinical trial design and investigator-sponsored research, and has successfully managed core medical teams involved in product launch and life cycle management.
Global Market Experience
Vlad Vitoc has been involved in various geographical endeavors that encompass both US and global markets. His proven track record includes managing and influencing across science- and commercially-focused environments, demonstrating his capability to navigate complex market dynamics in the biotechnology and pharmaceutical sectors.